| Author | Kirchheiner, Julia | dc.contributor.author |
| Author | Rodriguez-Antona, Cristina | dc.contributor.author |
| Date of accession | 2022-05-20T11:33:27Z | dc.date.accessioned |
| Available in OPARU since | 2022-05-20T11:33:27Z | dc.date.available |
| Date of first publication | 2009 | dc.date.issued |
| Language | en | dc.language.iso |
| Publisher | Universität Ulm | dc.publisher |
| Keyword | ADVERSE DRUG-REACTIONS | dc.subject |
| Keyword | SEROTONIN REUPTAKE INHIBITORS | dc.subject |
| Keyword | STATE PLASMA-CONCENTRATIONS | dc.subject |
| Keyword | CYP2D6 GENOTYPE | dc.subject |
| Keyword | VENLAFAXINE PHARMACOKINETICS | dc.subject |
| Keyword | HYDROXYLATION PHENOTYPE | dc.subject |
| Keyword | ATYPICAL ANTIPSYCHOTICS | dc.subject |
| Keyword | SCHIZOPHRENIC-PATIENTS | dc.subject |
| Keyword | ULTRARAPID METABOLISM | dc.subject |
| Keyword | HALOPERIDOL TREATMENT | dc.subject |
| Dewey Decimal Group | DDC 610 / Medicine & health | dc.subject.ddc |
| Title | Cytochrome P450 2D6 Genotyping Potential Role in Improving Treatment Outcomes in Psychiatric Disorders | dc.title |
| Resource type | Wissenschaftlicher Artikel | dc.type |
| Institution | UKU. Institut für Naturheilkunde und Klinische Pharmakologie | uulm.affiliationSpecific |
| DCMI Type | Text | uulm.typeDCMI |
| Category | Publikationsnachweise | uulm.category |
| DOI (external) | 10.2165/00023210-200923030-00001 | dc.identifier.doiExternal |
| Source - Title of source | CNS Drugs | source.title |
| Source - Place of publication | Springer | source.publisher |
| Source - Volume | 23 | source.volume |
| Source - Issue | 3 | source.issue |
| Source - Year | 2009 | source.year |
| Source - From page | 181 | source.fromPage |
| Source - To page | 191 | source.toPage |
| Source - ISSN | 1172-7047 | source.identifier.issn |
| Community | Universitätsklinikum Ulm | uulm.community |
| WoS | 000265309200001 | uulm.identifier.wos |
| Bibliography | uulm | uulm.bibliographie |
